Skip to main content
. 2021 Mar 18;127(11):1816–1826. doi: 10.1002/cncr.33448

Figure 3.

Figure 3

Kaplan‐Meier analysis of PFS. The median PFS (along with the 95% CI) is plotted for all treated patients (isatuximab plus carfilzomib). CI indicates confidence interval; PFS, progression‐free survival.